Polypharmacy increases the risk of drug-drug interactions (DDIs). Combining epidemiological studies with pharmacokinetic modeling, we detected and evaluated high-dimensional DDIs among 30 frequent drugs. Multidrug combinations that increased the risk of myopathy were identified in the US Food and Drug Administration Adverse Event Reporting System (FAERS) and electronic medical record (EMR) databases by a mixture drug-count response model. CYP450 inhibition was estimated among the 30 drugs in the presence of 1 to 4 inhibitors using in vitro / in vivo extrapolation. Twenty-eight three-way and 43 four-way DDIs had significant myopathy risk in both databases and predicted increases in the area under the concentration-time curve ratio (AUCR) >2-fold. The high-dimensional DDI of omeprazole, fluconazole, and clonidine was associated with a 6.41-fold (FAERS) and 18.46-fold (EMR) increased risk of myopathy local false discovery rate (<0.005); the AUCR of omeprazole in this combination was 9.35. The combination of health record informatics and pharmacokinetic modeling is a powerful translational approach to detect high-dimensional DDIs.
Polypharmacy increases the risk of drug-drug interactions (DDIs). Combining epidemiological studies with pharmacokinetic modeling, we detected and evaluated high-dimensional DDIs among 30 frequent drugs. Multidrug combinations that increased the risk of myopathy were identified in the US Food and Drug Administration Adverse Event Reporting System (FAERS) and electronic medical record (EMR) databases by a mixture drug-count response model. CYP450 inhibition was estimated among the 30 drugs in the presence of 1 to 4 inhibitors using in vitro / in vivo extrapolation. Twenty-eight three-way and 43 four-way DDIs had significant myopathy risk in both databases and predicted increases in the area under the concentration-time curve ratio (AUCR) >2-fold. The high-dimensional DDI of omeprazole, fluconazole, and clonidine was associated with a 6.41-fold (FAERS) and 18.46-fold (EMR) increased risk of myopathy local false discovery rate (<0.005); the AUCR of omeprazole in this combination was 9.35. The combination of health record informatics and pharmacokinetic modeling is a powerful translational approach to detect high-dimensional DDIs.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ High-dimensional drug interactions are occasionally investigated in vitro, but are rarely done in pharmacoepidemiology studies.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ For the first time, this study discovered and validated highdimensional drug interaction-induced myopathy using two independent health record databases. This study further investigated their pharmacokinetics mechanisms through the in vitro / in vivo extrapolation.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
þ Using the mixture drug-count-response model (MDCM), for the first time this study estimated the maximum highdimensional drug interaction-induced myopathy risks. In particular, the maximum myopathy risk reaches 1.0 in the FAERS. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ Using both IVIVE high-dimensional drug interaction AUCR prediction and MDCM-based data mining from two databases, we demonstrate the significantly increased myopathy risk among (omeprazole, clonidine, fluconazole), and via inhibition of CYP3A and CYP2C19 enzymes.
Drug-drug interactions (DDIs) are a common cause of adverse drug events (ADEs). [1] [2] [3] In the United States alone, each year an estimated 195,000 hospitalizations and 74,000 emergency room visits are the result of DDIs. National Health and Nutrition Examination Survey data published in 2010 4 showed that the number of patients using two or more prescription drugs increased from 25.4% to 31.2% in 10 years. In particular, more than 64% of elderly individuals took three or more prescription drugs, and 37% took five or more prescription drugs. 4 In the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data, 35% of reports include three or more prescription drugs, and 20% reports have five or more prescription drugs.
In order to evaluate clinical effects and molecular mechanisms of DDIs, clinical pharmacokinetic (PK) studies, pharmacoepidemiologic studies, and in vitro PK experiments have been routinely utilized. One salient example is that of the breast cancer hormonal therapy, tamoxifen. The formation of its active metabolite, endoxifen, was inhibited by the concomitant selective serotonin reuptake inhibitor paroxetine in a clinical pharmacokinetics study. 5 In vitro metabolism studies revealed that this is due to paroxetine's strong inhibition of the tamoxifen biotransformation to endoxifen via the CYP2D6 pathway. 6 In a follow-up pharmacogenetic study, breast cancer patients with CYP2D6 loss of function variants have a higher risk of disease relapse and a lower incidence of hot flush. 7 The clinical consequence of treating breast cancer and depression using tamoxifen and selective serotonin reuptake inhibitors (SSRIs) was reviewed, 8 and a call made for further investigation. Another example is the sedation agent midazolam. Coadministration of midazolam and the ergosterol synthesis inhibitor ketoconazole has been identified to reduced subjects' cognitive function. 9 In clinical PK and in vitro experiments, midazolam metabolism was inhibited by ketoconazole through the CYP3A pathway, 10, 11 leading to increased midazolam exposure. 12 These examples clearly demonstrate that the translational significance of drug interaction studies relies on both clinical and molecular pharmacology evidence. As described by Hennessy and Flockhart, 13 an integrated informatics, epidemiology, and pharmacology approach has the potential to accelerate the translational drug interaction studies. Pioneered by Tatonetti et al., 14 FAERS and electronic medical records were utilized to generate and validate drug-ADE and drug-drug-ADE associations. In a follow-up study, Lorberbaum et al. demonstrated that patients coadministrated ceftriaxone and lansoprazole were 1.4 times as likely to have a prolonged QT prolongation than the administrated single drug in both electronic medical record (EMR) and FAERS data. Further validation showed that the ceftriaxone/ lansoprazole drug interaction was due to an hERG channel blocker in a patchclamp experiment system. 15 Duke et al. proposed a text-mining strategy for DDI molecular pharmacology evidence discovery from the public literature, 16 which discovered 13,197 potential DDIs. In the follow-up in vitro study, Han et al. validated the loratadine-simvastatin myotoxicity interaction, and its increased myopathy risk in both EMR and FAERS databases. 17 Similarly, Schelleman et al. examined the increased risk of hypoglycemia with coadministration of fibrates and statins in sulfonylurea users in a pharmacoepidemiology study. 18 This DDI was further evaluated in an in vitro / in vivo extrapolation (IVIVE) pharmacokinetic model. High-dimensional drug interactions (HDDIs), i.e., DDIs with three or more drugs, have not yet been broadly investigated. There are a few examples of clinical PK studies, in vitro PK experiments, and IVIVE PK models that evaluate interactions among three or more drugs. Coadministration of gemfibrozil and itraconazole were shown to increase repaglinide plasma exposure to a greater extent than either one alone. 19 Zhang et al. found an additive PK model, including mechanism-based and competitive components, best described the in vitro inhibition of midazolam metabolism by erythromycin, diltiazem, and their metabolites. 20 Through IVIVE, this model was confirmed in vivo in mice. 21 On the other hand, to our knowledge, there are no studies of threeway drug interactions using pharmacoepidemiology studies. Proportional reporting ratio (PRR), 22 the reporting odds ratio (ROR), 23 the information component (IC), 24 and the empirical Bayes geometric mean (EBGM) 25 have been proposed for detection of drug-ADE signals. However, these methods are focused on ADE detection for single drugs, not drug combinations. To overcome this limitation, we recently developed a new method, a mixture drug-count response model (MDCM). This model focuses on detecting HDDIs and characterizes the drug-count response relationship between the number of coadministered drugs and an ADE. We successfully demonstrated its statistical and computational performance in a recent publication. 26 In this study we used this newly developed MDCM to detect HDDIs that lead to increased risk of myopathy in two independent databases: the Indiana Network of Patient Care -CDM (INPC-CDM) electronic medical record and FAERS. Using in vitro cytochrome P450 (CYP) inhibition data and mechanistic static in vitro, in vivo DDI predictions, we evaluated the potential pharmacological mechanisms of these HDDIs.
RESULTS

Drug selections
As our MDCM is computationally expensive, we limited this analysis to the top 30 drugs. After normalizing drug names by their DrugBank IDs, 1,238 and 1,716 FDA-approved drugs were identified in the INPC-CDM and FAERS datasets. Of these, after selecting 268 drugs and 172 drugs in INPC-CDM and FAERS, respectively, had a relative frequency 0.5%, with 119 drugs overlapping both databases. Among these 119 drugs, 95 have reported myopathy risk according to SIDER (http:// sideeffects.embl.de/). We curated the in vitro pharmacokinetic data for these 119 drugs to determine their potential to interact via CYP450 inhibition. Nine drugs had reported fraction metabolism (f m ) by human CYP450 enzymes. These drugs were evaluated as substrates for the prediction of area under the concentration-time curve ratio in the presence to absence of inhibitor (AUCR). Published competitive inhibition (k i ) values for at least one CYP450 enzyme were available for 64 of the drugs. The top 23 drugs with inhibition ranked by 
INPC-CDM and FAERS show strikingly different drug-count myopathy response mixture models
Under the MDCM, each drug combination has a probability of being assigned to either a drug-count myopathy response model or a constant myopathy risk model. The drug-count response model and constant model share the same myopathy risk when subjects take only one drug. The drug-count myopathy response model captures the overall trend of the nonlinear relationship between the number of coadministered drugs and myopathy risk. It also characterizes a constant myopathy risk and the maximum myopathy risk as the number of coadministered drugs increases. Strikingly, the drug-count response model demonstrated very different trends between drug combinations and myopathy risk in INPC-CDM and FAERS databases. INPC-CDM had a constant myopathy risk of 0.42, and a maximum risk of 0.74; while FAERS data shows a constant risk of 0.07 and a maximum risk of 1.0 ( Figure 2 ). In the INPC-CDM, the maximum myopathy risk occurs when the four drugs are coadministered. However, in the FAERS the myopathy risk continues to increase beyond five-drug combinations.
Overlapping drug combinations in INPC-CDM and FAERS
The drug-count-response mixture model generates a local false discovery rate (LFDR) statistic that allows us to differentiate drug combinations that are more likely to follow the drug-response myopathy risk model than the constant risk model. Figure 3 shows the percentage of overlapping drug combinations that are shared between the two databases, with an LFDR of 0.05. We see strong and consistent evidence of increased myopathy risk with an overlap of 37-40% of two-way to five-way drug combinations shown to increase myopathy risk in both databases.
The overall trend of HDDIs in pharmacokinetics predicted by IVIVE One common mechanism of DDI occurs through inhibition of drug metabolism. In order to assess whether the potential DDIs identified by pharmacoepidemiology evidence are due to pharmacokinetic drug interactions, we used IVIVE to evaluate the change in drug exposure between a drug administered alone and coadministered with two, three, or more drugs. In the IVIVE prediction, CYP substrates and CYP inhibitors are differentially defined. Among our 30 selected drugs, nine are CYP substrates with curated f m , f e , and f u data from the literature. We also obtained the k i , f u , and C max for 23 drugs identified as CYP inhibitors. These data were combined through IVIVE to predict the AUCR for 156 two-way, 1,302 three-way, 6,971 four-way, and 26,901 five-way drug interaction combinations ( Figure 4 ). When we look at all the AUCR data under different dimensions of drug interactions, their medians, 75 th percentiles, and the maximum AUCRs all reach a maximum plateau with the coadministration of three drugs.
Sensitivity analyses of significant three-way drug interactions
Among the nine substrates and 23 inhibitors, 28 three-way drug interactions have a predicted AUCR >2 and an LFDR from the MDCM model <0.05. We hypothesized that among these drugs, the risk of myopathy would increase as the number of cooccurring drugs increased. Therefore, for each three-drug combination we evaluated myopathy risk between individuals taking one drug vs. any two-drug combinations, and between two-drug and three-drug combinations. One drug-triplet showed a strong increasing trend in myopathy risk: omeprazole, clonidine, and fluconazole ( Figure 5 ) after adjusting for the number of additional comedications, age, and gender. In the FAERS dataset, taking any two of these three drugs together increased the risk of myopathy by 1.88-fold compared to taking any of the drugs alone (P 5 0.012). Taking the three-drug combinations of omeprazole, clonidine, and fluconazole increased the risk of myopathy by 5.01-fold compared to the two-drug combinations (P 5 0.000012). In the INPC-CDM, taking any two of these drugs concurrently increased the risk of myopathy by 1.75-fold (P 5 7.8E-13) and taking all three together increased the risk by 4.18-fold (P 5 0.0069) compared to taking one drug and two drugs, respectively. Similar comparisons of two-and three-drug combinations to one-and two-drug combinations for the other 27 drug triplets examined did not reveal significantly increased myopathy risk in both datasets for other drug combinations (Supplementary Table S1 ).
The AUCRs of omeprazole due to the inhibition by clonidine and fluconazole alone or together were estimated from literature data using mechanistic static interaction models. 27 Omeprazole is a racemic mixture of R-and S-omeprazole. While both enantiomers are metabolized by CYP2C19 and CYP3A ( Figure 6 ), the f m 's for each pathway are slightly different (Table S2) . Fluconazole is a well-known CYP2C19 and CYP3A inhibitor, with a median k i value of 5.075 lM and 13.25 lM, respectively. [28] [29] [30] The k i of clonidine for CYP3A is 0.15 lM. 31 Incorporating these values into the IVIVE model (Eq. 4) predicts AUCRs of R-and S-omeprazole of 1.45 and 1.35, respectively, after the clonidine inhibition, and 5.06 and 5.17 after fluconazole inhibition. Following coadministration of the three drugs, the AUCRs of R-and S-omeprazole are predicted to be 9.35 and 8.51, respectively. Alternatively, the f m of omeprazole can also be estimated from a pharmacogenetics PK study. Venkatakrishnan et al. calculated the f m of omeprazole from the AUCR of CYP2C19 extensive metabolizer and poor metabolizer 32, 33 (f m 5 0.87 for CYP2C19). Using this f m , the AUCR estimated from IVIVE is predicted to be 1.14 after clonidine inhibition; 5.99 after fluconazole inhibition; and 7.69 after inhibition by both drugs. 
DISCUSSION
Using the MDCM, we mined the HDDIs among 30 common drugs in two independent health record databases. We identified a number of HDDIs that have increased risk of myopathy in both databases. This model further reveals interesting differences in the drug-count response relationship in the two databases. In the FAERS, the maximum myopathy risk goes to almost 1.0 as the dimension of drug combinations increases. Thus, a patient would be expected to experience a myopathy event if he/she takes a large number of drugs. On the other hand, the maximum myopathy risk in the INPC-CDM data is 0.72. However, because it was estimated from a case-control study, this number cannot be simply interpreted as a population maximum myopathy risk. Our 1:10 case control design has a higher myopathy case frequency (0.09) than the INPC-CDM population myopathy risk (0.067) reported previously. 16 Hence, we anticipate that the population maximum HDDI myopathy risk in the INPC-CDM data is less than 0.72. While we observe that the maximum myopathy risk is higher in the FAERS database than in the INPC-CDM database, it is extremely striking that the frequency in FAERS approaches one. Although the maximum myopathy risk in the INPC-CDM data is lower than that of FAERS, it is still an extremely common ADE.
Among the statistically significant three-way drug interactions identified from MDCM and validated by two databases, more stringent sequential comparisons are further conducted between one-drug vs. two-drug and two-drug vs. three-drug. We further demonstrated that omeprazole, clonidine, and fluconazole, exhibited statistically significantly increased myopathy risk from single drug to three-drug combinations in both databases.
In parallel to our MDCM model, we evaluated the potential CYP PK interactions among the 30 drugs. In the IVIVE HDDI prediction, one drug acts as the substrate and the other drugs are assumed to be reversible inhibitors of CYP enzymes. Substrate AUCR changes were predicted based on the curated in vitro PK data. The maximum predicted AUCR was reached with three-drug combinations. In contrast, the maximum HDDI myopathy risk observed in the two medical record databases did not occur until five drugs were coadministered. This suggests that additional mechanisms are responsible for the increased risk of myopathy observed with HDDIs. For instance, we have previously shown that the increased risk for myopathy with coadministration of loratadine and simvatstain is due to a pharmacodynamic mechanism in the muscle cell. 17 We have also shown that the increased risk of myopathy observed when chloroquine is coadministered with simvastatin is the result of increased lysosomal OATP1B1 protein degradation. 34 As the risk of myopathy consistently increased among two-way and three-way combinations of omeprazole, clonidine, and fluconazole, we closely examined the predicted AUCR using IVIVE for these combinations. Compared to the 1.5-5 fold increase in AUCR of R-and S-omeprazole when inhibited by only one drug, either clonidine or fluconazole, the coadministration of both drugs with omeprazole led to an AUCR of 8.5-9.4. As f m is a critical component of predicting the extent of interaction, we evaluated the interaction using both in vitro data and data from clinical pharmacogenetic study of CYP2C19 to determine omeprazole's f m . We estimated f m CYP2C19 (0.68) from in vitro data mining 37, 38 and the irreversible inhibition of potassium-hydrogen ATPase in the skeletal muscles. 39 Recently, Sansone et al. surveyed the Italian National Network of Pharmacovigilance Database and found that omeprazole was more frequently involved in reports of myopathy than any other nonstatin drugs. 40 From this evidences omeprazole is the primary candidate that induced myopathy. In addition, there were 16 case reports in the literature 41, 42 and summarized in a case series that associate the use of omeprazole with myopathy. 38 Among these 16 cases, two were identified as Asians, but race was not reported among the other cases. Similarly, in our database, the race data were incomplete and sometimes inaccurate. Hence, the race effect of omeprazole inducing myopathy remains unknown.
One limitation of the MDCM model is its large computational expense. Because of this, only a limited number of drugs (i.e., 30) could be screened for HDDI. Thus, screening steps are required to reduce the number of drugs. More research is needed to increase the computational efficiency of MDCM. Future research will also apply the MDCM model to evaluate the drug-count response patterns for other ADEs.
Although the mechanistic static model is a well-accepted screening tool for pharmacokinetic drug interactions, it may over-or underestimate the extent of interaction. Of note, our model only included reversible inhibition and did not consider gut wall metabolism effects of inhibitors. Thus, we may have underestimated the AUCR for orally administered drugs. While mechanistic static models have been established to predict the effect of mechanism-based inhibitors and CYP inducers, 43, 44 these models have not been validated with respect to HDDI among drugs that inhibit the same enzyme. Additionally, interactions in other pathways, such as drug transporters, could be included using more mechanistic and time-dependent modeling techniques. In addition, we utilized C max data from the literature without respect to the doses of drugs observed in the clinical records.
This study demonstrates the power to elucidate clinically significant HDDIs from clinical records. Using two unique datasets, ADE case reports from the FAERS and structured electronic medical record data from the INPC-CDM, we observed increasing trends in myopathy risk with higher medication burden. As a large number of DDIs are the result of PK interactions at the level of CYP enzymes, we also estimated the increased exposure of nine substrate drugs in the presence of two, three, or more inhibitors. Although we demonstrated that decreased clearance of drugs due to CYP inhibition is one source of the increased myopathy risk among polypharmacy patients, this mechanism is unable to fully explain the increased risk of myopathy observed in subjects taking four or more medications. As our computational efficiency expands to allow for the evaluation of a greater number of drugs using our MDCM model, additional pharmacokinetic and pharmacodynamic mechanisms of interaction will need to be considered to further account for the increased risk of ADEs observed in polypharmacy patients. The INPC-CDM consists of structured data detailing medical conditions, medications, and lab tests of patients. Using this dataset, we identified myopathy patients, as defined in our previous article (Duke et al., Table S6   16 ). The myopathy case definition contains both severe symptoms, such as rhabdomyolysis, and mild symptoms, such as muscle weakness. The myopathy cases include the first myopathy event recorded for a patient and cases in which no other myopathy event occurred within the past 6 months. For each case, 10 controls were selected from records within the same time-frame (anchor time-matched) and matching demographic criteria. These controls did not have any myopathy events recorded in the INPC-CDM dataset. Under each anchor time in both cases and matched controls, a 1-month drug exposure window was generated. Drugs were coded as present if their prescription time periods overlapped with the drug exposure window. Drug names were normalized to their DrugBank IDs. The INPC-CDM dataset has 450,673 cases and 4,506,730 controls. This case/control design for myopathy using the INPC-CDM database was similar to that used in our previous publications. 17, 26, 44 FDA adverse event reporting system (FAERS) Unlike INPC-CDM, FAERS is a case reporting system, not a longitudinal database. In FAERS, myopathy cases were similarly identified using the same terms we used in the INPC-CDM (Table S1 ). There were 136,791 myopathy cases, and 3,969,842 controls identified in the FAERS. The drug names were mapped to their DrugBank IDs.
Drug selection criteria and data curation
Only FDA-approved drugs included. Selected by frequency >0.5% in both INPC and FAERS databases. Myopathy risk identified in SIDER. Limited to 30 drugs due to computational expense of MDCM.
Pharmacokinetic parameters required for IVIVE of AUCR (C max , f u , f m , K m , V max , K i ) were curated from Goodman and Gilman 45 or published literature identified in PubMed. C max obtained from literature review 45 was used as the inhibitor concentration [I] . This conservative approach to estimate maximal inhibition has been used by others. 46 If a pharmacokinetics parameter was reported in multiple sources, the sample mean was used.
The f m data were curated from several different types of published studies. Most of the f m data were estimated from substrate depletion studies in human liver microsomes, in which the substrate is incubated with or without CYP-selective inhibitors. 47 The percentage inhibition caused by the CYP-selective inhibitor reflects the f m of drug for this CYP. The f m can also be estimated through in vivo pharmacokinetic studies comparing the AUC or clearance of a substrate in the presence and absence of a CYP-selective inhibitor 48 or in a pharmacogenetic PK study where it can be calculated from the fold-change in exposure of a victim drug in extensive metabolizers compared to poor metabolizers. 26, 27 Mixture drug-count-response model for the high-dimensional drug effect on myopathy In 2015, our group developed a mixture drug-count-response model (MDCM) for identifying HDDI-induced ADEs. 26 In the MDCM, i is denoted as the number of drugs for i-way drug combinations; j is the jth i-way drug combinations; n ij is the total number of patients taking a jth i-way drug combinations; and y ij is the number of cases among those n ij patients. The parameter p represents the proportion of drug combinations that follow the drug-count-response model. The probability distribution of y ij is defined as the following mixture model:
Pðy ij Þ5ð12pÞBinðn ij ; y ij ; P const Þ1p Binðn ij ; y ij ; P count Þ (1) where P const and P count represent a constant ADE risk probability and a drug-count-response ADE risk probability respectively: P const 5 c3expðb 0 Þ 11expðb 0 Þ ; P const 5 c3expðb 0 1b 1 ði21ÞÞ 11expðb 0 1b 1 ði21ÞÞ :
After applying MDCM to both FAERS and INPC-CDM data, a local false discovery rate (LFDR) is calculated for each drug combinations. An LFDR demonstrates the significance of a drug combinations that follows the drug-count-response model. Then all the drug combinations are ranked based on the LFDR accordingly.
LFDR5 ð12pÞBinðn ij ; y ij ; P const Þ ð12pÞBinðn ij ; y ij ; P const Þ1pBinðn ij ; y ij ; P const Þ
This MDCM allows different drug combinations to share the same risk probabilities, either a constant risk or a drug-count-response risk. This strategy overcomes the small sample size in each high-dimensional drug combinations. In this study we evaluated the dimension of the drugs taken from a single drug to five coadministered drugs.
Sensitivity data analysis
Overlapping and mutually validated significant (LFDR <0.05) highdimensional drug combinations between FAERS and INPC-CDM data were further evaluated. In the follow-up sensitivity analyses, a sequential logistic regression was conducted to compare myopathy risk between any two adjacent dimensions of drug combinations; for example, one-way vs. two-way, two-way vs. three-way, etc. The logistic regression model included the demographic, and the number of other comedications as covariates to adjust for the confounding effects. Clint;i , where fm i is the fraction of metabolism by CYP enzyme (i), and P n i51 fm i 51 where n is the number of metabolism routes.
When there is only one inhibitor and one metabolizing enzyme, Ito et al. 27, 49 showed that the change in clearance in the presence of a DDI can be predicted as If there are inhibitors on the same enzyme, the inhibitors' effects are assumed to fit an additive model. 50 The AUCR for inhibition of a single enzyme then becomes: 
AUCR5 Cl
We used this method to predict the AUCR for each substrate drug in the presence of one to four inhibitors.
Additional Supporting Information may be found in the online version of this article.
